B+
Bull case
20%
Probability
Target price
$656.25
+54.4% vs current
VRTX
VertexBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$530.16
+24.7% vs current
B-
Bear case
20%
Probability
Target price
$330.00
-22.4% vs current
AI sentiment snapshot
Latest data as of 2026-02-14
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+70.4
Score
AI commentary
Consensus shows modest upside from the anchor with wide dispersion (low ~330, high ~656). Market tone is cautiously constructive; near-term sentiment will hinge on earnings and R&D outcomes, and the buy view rests on asymmetric upside from successful catalysts despite a modest base uplift.
RankAlpha Sentiment AI - 2026-02-14
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 FY2026 results (estimated)High impact
Quarterly results and guidance could prompt near-term re-pricing; date estimated on typical reporting cadence.
2026-09-30eventPipeline readouts / regulatory filingsHigh impact
Phase readouts or regulatory submissions for non-CF programs could materially shift growth expectations; date is a conservative window end.
2027-02-14catalystCommercial growth and label expansionHigh impact
Sustained CFTR uptake, label expansions, or commercialization of new indications would underpin medium-term re-rating; date set conservatively at one year.
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-14 • Updated nightlySource: Internal modelMethodology